Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes.

[5][6] It was approved for use in the United States in January 2015,[7][8] for use in the European Union in November 2016,[6] and for use in Australia in December 2016.

[2] In the United States empagliflozin/linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

[5][6] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).

[6] The combination preparation was developed and is marketed by Boehringer Ingelheim and Eli Lilly and Company under the brand name Glyxambi.